早期免疫抑制辅助UDCA对原发性胆汁性肝硬化合并自身免疫性肝炎患者疗效的影响

肝脏 ›› 2018, Vol. 23 ›› Issue (11): 993-995.

早期免疫抑制辅助UDCA对原发性胆汁性肝硬化合并自身免疫性肝炎患者疗效的影响

姚路静, 昝松波, 姬红波, 朱叶珊, 白瑞峰, 王强

471002 河南洛阳市第三人民医院消化内科

收稿日期:2018-02-06 出版日期:2018-11-30 发布日期:2020-04-28

Received:2018-02-06 Online:2018-11-30 Published:2020-04-28

摘要/Abstract

摘要： 目的探讨早期免疫抑制辅助熊去氧胆酸(UDCA)对原发性胆汁性肝硬化(PBC)合并自身免疫性肝炎(AIH)患者治疗应答率、生化及免疫学指标的影响。方法研究对象选取我院2008年4月至2016年10月收治PBC合并AIH患者共50例,根据治疗方案不同分为对照组(25例)和观察组(25例),分别采用UDCA单用和在此基础上加用糖皮质激素辅助治疗;比较两组患者ALT应答率、ALP应答率、IgG应答率,治疗前后ALT、AST、球蛋白、总胆红素、ALP、γ-谷氨酰转肽酶、IgG及IgM水平。结果观察组患者ALT应答率、ALP应答率及IgG应答率均明显高于对照组(P<0.05);观察组患者治疗后ALT、AST、球蛋白、总胆红素、ALP及γ-谷氨酰转肽酶水平均明显优于对照组、治疗前(P<0.05);观察组患者治疗后IgG和IgM水平均明显优于对照组、治疗前(P<0.05)。结论早期免疫抑制辅助UDCA用于PBC合并AIH患者可有效提高治疗应答率,改善生化和免疫学指标,价值优于UDCA单用。

关键词: 糖皮质激素, UDCA, 原发性胆汁性肝硬化, 自身免疫性肝炎

姚路静, 昝松波, 姬红波, 朱叶珊, 白瑞峰, 王强. 早期免疫抑制辅助UDCA对原发性胆汁性肝硬化合并自身免疫性肝炎患者疗效的影响[J]. 肝脏, 2018, 23(11): 993-995.

参考文献

[1] European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol, 2017, 67: 145-172.
[2] Lammers WJ, Hirschfield GM, Corpechot C, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology, 2015, 149: 1804-1812.
[3] Carbone M, Sharp SJ, Flack S, et al. The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology, 2016, 63: 930-950.
[4] Shuai Z, Wang J, Badamagunta M, et al. The fingerprint of antimitochondrial antibodies and the etiology of primary biliary cholangitis. Hepatology, 2017, 65: 1670-1682.
[5] 中华医学会肝病学分会,中华医学会消化病学分会,中华医学会感染病学分会.原发性胆汁性肝硬化(又名原发性胆汁性胆管炎)诊断和治疗共识(2015).临床肝胆病杂志,2015,31: 1980-1988.
[6] 周璐,焦国慧,王邦茂.自身免疫性肝炎临床实践指导.天津科学技术出版社,2015: 223-244.
[7] Beuers U, Gershwin ME, Gish RG, et al. Changing nomenclature for PBC: from cirrhosis to cholangitis. Clin Gastroenterol Hepatol, 2015, 13: 1867-1869.
[8] Abdollahi MR, Somi MH, Faraji E. Role of international criteria in the diagnosis of autoimmune hepatitis. World J Gastroenterol, 2013, 19: 3629-3633.
[9] Wang Q, Selmi C, Zhou X, et al. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis. J Autoimmun, 2013, 41: 140-145.
[10] Muratori P, Fabbri A, Lalanne C, et al. Autoimmune liver disease and concomitant extrahepatic autoimmune disease. Eur J Gastroenterol Hepatol, 2015, 27: 1175-1179.
[11] Floreani A, Franceschet I, Cazzagon N. Primary biliary cirrhosis: overlaps with other autoimmune disorders. Semin Liver Dis, 2014, 34: 352-360.
[12] Yang F, Wang Q, Wang Z, et al. The natural history and prognosis of primary biliary cirrhosis with clinical features of autoimmune hepatitis. Clin Rev Allergy Immunol, 2016, 50: 114- 123.
[13] Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med, 2016, 375: 631-643.
[14] Wang Q, Yang F, Miao Q, et al. The clinical phenotypes of autoimmune hepatitis: a comprehensive review. J Autoimmun, 2016, 66: 98-107.
[15] Samur S, Klebanoff M, Banken R, et al. Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Hepatology, 2017, 65: 920 -928.